Teva Pharmaceuticals

iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors

Retrieved on: 
Wednesday, March 6, 2024

“Expanding our board with industry leaders and oncology veterans with commercial, scientific, and corporate portfolio strategy experience is of the utmost importance for iTeos.

Key Points: 
  • “Expanding our board with industry leaders and oncology veterans with commercial, scientific, and corporate portfolio strategy experience is of the utmost importance for iTeos.
  • After the recent appointment of Servier’s David Lee, we are thrilled to welcome Jill DeSimone to our Board of Directors during an important time in iTeos’ evolution.
  • “By leveraging its comprehensive knowledge of tumor biology, iTeos has advanced a portfolio of promising therapeutic candidates addressing key immunological pathways involved in the development of cancer,” said Ms. DeSimone.
  • in Pharmacy from Northeastern University and completed a fellowship with the Wharton School of the University of Pennsylvania.

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

Retrieved on: 
Saturday, February 24, 2024

Teva is Alvotech’s strategic partner for the exclusive commercialization of SIMLANDI in the United States.

Key Points: 
  • Teva is Alvotech’s strategic partner for the exclusive commercialization of SIMLANDI in the United States.
  • SIMLANDI is the first high-concentration, citrate-free biosimilar to Humira that has been granted an interchangeability status by the FDA, and will qualify for interchangeable exclusivity for the 40mg/0.4ml injection.
  • An interchangeable biosimilar may be substituted at the pharmacy without consulting the prescriber, much like generic drugs are routinely substituted for brand name drugs.
  • Alvotech handles development and manufacturing, and Teva is responsible for U.S. commercialization, which leverages Teva’s extensive experience and sales and marketing infrastructure.

AdhereTech Announces Appointment of Paul Sekhri to Board of Directors

Retrieved on: 
Wednesday, February 21, 2024

SUMMIT, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- AdhereTech, Inc., the market leading provider of real-time medication adherence solutions proven to help patients remain on their medications longer, improving patient outcomes and pharma company revenue, today announces that long-time life sciences industry executive, Paul Sekhri, has joined the Board of Directors, effective February 7, 2024.

Key Points: 
  • SUMMIT, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- AdhereTech, Inc., the market leading provider of real-time medication adherence solutions proven to help patients remain on their medications longer, improving patient outcomes and pharma company revenue, today announces that long-time life sciences industry executive, Paul Sekhri, has joined the Board of Directors, effective February 7, 2024.
  • “We are excited to have Paul join the AdhereTech Board of Directors,” commented Neale Trangucci, Chair of the Board.
  • Paul Sekhri added: “I welcomed the opportunity to join the Board of AdhereTech as I see that the company’s Aidia real-time adherence technology can effectively address a major issue - non-adherence to medication.
  • I look forward to working with my fellow Board members and the management team to help ensure AdhereTech’s solutions get to those who need them.”

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

Retrieved on: 
Saturday, February 24, 2024

Teva is Alvotech’s strategic partner for the exclusive commercialization of SIMLANDI in the United States.

Key Points: 
  • Teva is Alvotech’s strategic partner for the exclusive commercialization of SIMLANDI in the United States.
  • An interchangeable biosimilar may be substituted at the pharmacy without consulting the prescriber, much like generic drugs are routinely substituted for brand name drugs.
  • As the only interchangeable adalimumab biosimilar with the high-concentration formulation, SIMLANDI can be substituted for Humira at the pharmacy level, subject to state pharmacy laws.
  • Alvotech handles development and manufacturing, and Teva is responsible for U.S. commercialization, which leverages Teva’s extensive experience and sales and marketing infrastructure.

Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting

Retrieved on: 
Tuesday, February 20, 2024

“These results from the first-in-human trials of anti-TL1A (TEV-’574) are exciting because they show that it effectively engages with the TL1A target, supports its safety profile and is well-tolerated.

Key Points: 
  • “These results from the first-in-human trials of anti-TL1A (TEV-’574) are exciting because they show that it effectively engages with the TL1A target, supports its safety profile and is well-tolerated.
  • “We are currently investigating the efficacy and safety of anti-TL1A (TEV-’574) in IBD through the RELIEVE UCCD Phase 2 trial, which features an innovative and efficient basket study design allowing the inclusion of patients with either type of IBD (ulcerative colitis and Crohn’s disease).
  • Each company will equally share the development costs globally and net profits and losses in major markets, with other markets subject to a royalty arrangement, and Sanofi will lead the development of the Phase 3 program.
  • Teva will lead commercialization of the product in Europe, Israel and specified other countries, and Sanofi will lead commercialization in North America, Japan, other parts of Asia and the rest of the world.

VALISURE ANNOUNCES NEW VENTURE PARTNERS AND EXPANSION OF LEADERSHIP TEAM

Retrieved on: 
Wednesday, February 28, 2024

NEW HAVEN, Conn., Feb. 28, 2024 /PRNewswire/ -- Valisure, a healthcare industry pioneer for independent quality assurance in pharmaceutical drugs, has recently received substantial investments from leading healthcare venture capital firms to accelerate Valisure's rapid growth and impact. Concurrently, the company is pleased to announce key leadership developments, including appointing a highly experienced healthcare leader as CEO and additional expansion of its executive team.

Key Points: 
  • Concurrently, the company is pleased to announce key leadership developments, including appointing a highly experienced healthcare leader as CEO and additional expansion of its executive team.
  • Valisure has gained global recognition for its commitment to ensuring the safety and quality of medications through its highly impactful, independent testing.
  • "I look forward to collaborating with the talented team and enabling Valisure to expand its work with the industry to strategically address these issues."
  • Likewise, Wolfgang Hinz, Ph.D., has assumed a pivotal leadership position as the Chief Scientific Officer of Valisure.

Global Healthcare Executive Jill DeSimone Joins Swim Across America Board of Directors

Retrieved on: 
Thursday, February 15, 2024

CHARLOTTE, N.C., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Swim Across America, a national nonprofit dedicated to providing grants for cancer research and patient programs and raising funds through swimming events, is pleased to announce that Jill DeSimone, a global pharmaceutical executive, has been appointed to the Swim Across America Board of Directors. Jill's career included championing excellence in patient care for serious diseases, while igniting scalable growth and agility in the healthcare marketplace. She held positions of executive leadership for more than 30 years, culminating in eight years as president of Oncology for Merck.

Key Points: 
  • After a Successful Career with Oncology Pharmaceutical Companies, Jill DeSimone is Making Waves in the Fight Against Cancer
    CHARLOTTE, N.C., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Swim Across America , a national nonprofit dedicated to providing grants for cancer research and patient programs and raising funds through swimming events, is pleased to announce that Jill DeSimone, a global pharmaceutical executive, has been appointed to the Swim Across America Board of Directors.
  • "One of my greatest joys has been volunteering and encouraging many of my colleagues and friends to volunteer with Swim Across America," says Jill DeSimone.
  • "Jill has been supporting Swim Across America for many years," commented Pam Ryan, Swim Across America board chair.
  • Swim Across America was founded in 1987 with its first open water charity swim in Long Island Sound.

Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors

Retrieved on: 
Thursday, February 8, 2024

“We are excited to welcome Ivana to our board of directors,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.

Key Points: 
  • “We are excited to welcome Ivana to our board of directors,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
  • Under her strong leadership, Vigil has evolved from inception through IPO, to an organization with two clinical-stage development programs.
  • Dr. Magovčević-Liebisch has served on the Board of Directors of Absci, Aeglea Therapeutics and Applied Genetic Technologies Corporation.
  • I look forward to working with Peter, the board, and the executive team to develop multiple promising drug candidates to improve patient lives.”

Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer

Retrieved on: 
Tuesday, February 6, 2024

BURLINGAME, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of Jeffrey Arcara as Chief Business Officer.

Key Points: 
  • BURLINGAME, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of Jeffrey Arcara as Chief Business Officer.
  • “Corvus is leading the development of ITK inhibition as a platform opportunity across oncology and immune diseases.
  • The addition of Jeff as chief business officer strengthens our ability to maximize the potential of our ITK programs, both internally and through partnerships.
  • I look forward to leveraging my industry experience, including in oncology and immunology, to help drive the success of Corvus’ pipeline,” said Mr. Arcara.

Michael Graham Joins Enzymedica as Vice President of Operations

Retrieved on: 
Tuesday, February 6, 2024

VENICE, Fla., Feb. 6, 2024 /PRNewswire/ -- Enzymedica , a leading provider of digestive supplements, is pleased to announce the appointment of Michael Graham as the Vice President of Operations.

Key Points: 
  • VENICE, Fla., Feb. 6, 2024 /PRNewswire/ -- Enzymedica , a leading provider of digestive supplements, is pleased to announce the appointment of Michael Graham as the Vice President of Operations.
  • As Vice President of Operations, Graham will play a key role in optimizing Enzymedica's supply chain, manufacturing processes and overall operational efficiency.
  • "We are excited to welcome Michael Graham to Enzymedica," says Scott Sensenbrenner, CEO of Enzymedica.
  • With Graham as Vice President of Operations, the company is well-positioned to strengthen its operational capabilities, ensuring the continued delivery of high-quality products to its customers.